353 related articles for article (PubMed ID: 30652006)
1. Genetics of narcolepsy.
Miyagawa T; Tokunaga K
Hum Genome Var; 2019; 6():4. PubMed ID: 30652006
[TBL] [Abstract][Full Text] [Related]
2. Whole-genome analysis of monozygotic Brazilian twins discordant for type 1 narcolepsy: a case report.
Campos JHC; Aguilar ACR; Antoneli F; Truzzi G; Briones MRS; Ferreira RC; Coelho FMS
BMC Neurol; 2022 Nov; 22(1):439. PubMed ID: 36401198
[TBL] [Abstract][Full Text] [Related]
3. High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2.
Hamdan S; Wasling P; Lind A
Int J Immunogenet; 2024 Jun; ():. PubMed ID: 38898624
[TBL] [Abstract][Full Text] [Related]
4. Narcolepsies, update in 2023.
Barateau L; Pizza F; Chenini S; Peter-Derex L; Dauvilliers Y
Rev Neurol (Paris); 2023 Oct; 179(7):727-740. PubMed ID: 37634997
[TBL] [Abstract][Full Text] [Related]
5. Assessment of glymphatic function in narcolepsy using DTI-ALPS index.
Gumeler E; Aygun E; Tezer FI; Saritas EU; Oguz KK
Sleep Med; 2023 Jan; 101():522-527. PubMed ID: 36535226
[TBL] [Abstract][Full Text] [Related]
6. Management of Narcolepsy.
Barateau L; Lopez R; Dauvilliers Y
Curr Treat Options Neurol; 2016 Oct; 18(10):43. PubMed ID: 27549768
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
Nishino S; Kanbayashi T
Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
[TBL] [Abstract][Full Text] [Related]
8. Correlation between HLA-DQB1*06:02 and narcolepsy with and without cataplexy: approving a safe and sensitive genetic test in four major ethnic groups. A systematic meta-analysis.
Capittini C; De Silvestri A; Terzaghi M; Scotti V; Rebuffi C; Pasi A; Manni R; Martinetti M; Tinelli C
Sleep Med; 2018 Dec; 52():150-157. PubMed ID: 30321823
[TBL] [Abstract][Full Text] [Related]
9. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment.
Bassetti CLA; Adamantidis A; Burdakov D; Han F; Gay S; Kallweit U; Khatami R; Koning F; Kornum BR; Lammers GJ; Liblau RS; Luppi PH; Mayer G; Pollmächer T; Sakurai T; Sallusto F; Scammell TE; Tafti M; Dauvilliers Y
Nat Rev Neurol; 2019 Sep; 15(9):519-539. PubMed ID: 31324898
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Monaca C; Franco P; Philip P; Dauvilliers Y
Rev Neurol (Paris); 2017; 173(1-2):25-31. PubMed ID: 27838095
[TBL] [Abstract][Full Text] [Related]
11. The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study.
Ruoff C; Pizza F; Trotti LM; Sonka K; Vandi S; Cheung J; Pinto S; Einen M; Simakajornboon N; Han F; Peppard P; Nevsimalova S; Plazzi G; Rye D; Mignot E
J Clin Sleep Med; 2018 Jan; 14(1):65-74. PubMed ID: 29198301
[TBL] [Abstract][Full Text] [Related]
12. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
[TBL] [Abstract][Full Text] [Related]
13. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
14. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.
Williams RH; Tsunematsu T; Thomas AM; Bogyo K; Yamanaka A; Kilduff TS
J Neurosci; 2019 Nov; 39(47):9435-9452. PubMed ID: 31628177
[TBL] [Abstract][Full Text] [Related]
15. Narcolepsy during Childhood: An Update.
Rocca FL; Pizza F; Ricci E; Plazzi G
Neuropediatrics; 2015 Jun; 46(3):181-98. PubMed ID: 25961600
[TBL] [Abstract][Full Text] [Related]
16. Alexithymia, impulsiveness, emotion, and eating dyscontrol: similarities and differences between narcolepsy type 1 and type 2.
Del Bianco C; Ulivi M; Liguori C; Pisani A; Mercuri NB; Placidi F; Izzi F
Sleep Biol Rhythms; 2023 Jan; 21(1):39-50. PubMed ID: 38468909
[TBL] [Abstract][Full Text] [Related]
17. Sodium Oxybate Treatment in Pediatric Type 1 Narcolepsy.
Moresco M; Pizza F; Antelmi E; Plazzi G
Curr Drug Metab; 2018; 19(13):1073-1079. PubMed ID: 29512449
[TBL] [Abstract][Full Text] [Related]
18. Pseudotumor cerebri syndrome in a patient with narcolepsy type 1.
Rossor T; Lim M; VanDenEshof K; Gringras P
Eur J Paediatr Neurol; 2018 Jan; 22(1):194-198. PubMed ID: 29195824
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in treatment for narcolepsy.
Barateau L; Dauvilliers Y
Ther Adv Neurol Disord; 2019; 12():1756286419875622. PubMed ID: 31632459
[TBL] [Abstract][Full Text] [Related]
20. A preliminary study investigating the clinical potential of measuring cerebrospinal-fluid lactate levels in patients with narcolepsy type 1 and 2.
Fernandes M; Spanetta M; Placidi F; Izzi F; Negri F; Nuccetelli M; Bernardini S; Mercuri NB; Liguori C
Physiol Behav; 2023 Dec; 272():114371. PubMed ID: 37802459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
